Purpose Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and Re-186-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity.
|Number of pages||9|
|Journal||European Journal of Nuclear Medicine and Molecular Imaging|
|Publication status||Published - Nov 2011|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging